Physician profile
Daren Cheney
NPI 1124024039
$1,075.94
in general payments reported to CMS, 2019-2025
14 companies · $70.00 in 2025
The $70.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $263 · 2020: $102 · 2021: $40.83 · 2022: $161 · 2023: $195 · 2024: $245 · 2025: $70.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $509.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $509.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $210.45 | 2019-2024 | Nucala |
| E.R. Squibb & Sons, L.L.C. | $191.08 | 2020-2024 | Opdivo, Reblozyl |
| Alexion Pharmaceuticals, INC. | $125.00 | 2024 | Ultomiris |
| Pfizer INC. | $100.27 | 2019-2025 | |
| Novo Nordisk INC | $92.17 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.85 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $47.92 | 2020 | |
| Abbvie INC. | $42.29 | 2021-2024 | |
| Janssen Pharmaceuticals, INC | $40.00 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $37.50 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $35.00 | 2023 | Inpefa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.84 | 2022 | |
| Medtronic, INC. | $23.33 | 2023 | Venaseal |
| Biohaven Pharmaceuticals, INC. | $17.24 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daren Cheney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.